World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
76
Citations
18511
World Ranking
1928
National Ranking
172

Medicine

D-Index
76
Citations
18679
World Ranking
18882
National Ranking
1706

Alan Melcher publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Alan Melcher sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 342 publications — 72nd percentile

72% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Alan Melcher D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Alan Melcher sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 76 D-Index — 62nd percentile

62% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Alan Melcher is affiliated with the Institute of Cancer Research in the United Kingdom. Their research spans multiple areas within medicine, biochemistry, genetics, molecular biology, and immunology, with a particular focus on oncology, immunology, genetics, molecular biology, and infectious diseases.

Their main research topics include:

  • Virus-based gene therapy research
  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • CAR-T cell therapy research
  • Interferon and immune responses
  • Immune Cell Function and Interaction
  • Cancer Research and Treatments

Alan Melcher has frequently published in several venues, predominantly:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Journal for ImmunoTherapy of Cancer
  • Nature Communications
  • Cancer Research
  • Frontiers in Immunology

Recent publications by Alan Melcher include:

  • "Oncolytic virotherapy as immunotherapy", 2021, Science
  • "Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice", 2022, Science Translational Medicine
  • "Consensus guidelines for the definition, detection and interpretation of immunogenic cell death", 2020, Journal for ImmunoTherapy of Cancer
  • "Inflammatory microenvironment remodelling by tumour cells after radiotherapy", 2020, Nature reviews. Cancer
  • "STING and IRF3 in stromal fibroblasts enable sensing of genomic stress in cancer cells to undermine oncolytic viral therapy", 2020, Nature Cell Biology

Their collaborative work involves frequent co-authors such as Kevin J. Harrington, Malin Pedersen, Richard G. Vile, Emmanuel C. Patin, and Joan Kyula, indicating active involvement in multi-author scientific studies.

Best Publications

  • Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

    Lorenzo Galluzzi;Ilio Vitale;Sarah Warren;Sandy Adjemian

  • Inflammatory microenvironment remodelling by tumour cells after radiotherapy.

    Martin McLaughlin;Emmanuel C. Patin;Malin Pedersen;Anna Wilkins

  • Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression

    Alan Melcher;Stephen Todryk;Nicola Hardwick;Martin Ford

  • Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

    Frederick Arce Vargas;Andrew J S Furness;Kevin Litchfield;Kroopa Joshi

  • Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake.

    Stephen Todryk;Alan A. Melcher;Alan A. Melcher;Nicola Hardwick;Emmanouela Linardakis

  • Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade

    Adel Samson;Karen J. Scott;David Taggart;Emma J. West

  • A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.

    Laura Vidal;Hardev S. Pandha;Timothy A. Yap;Christine L. White

  • Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide

    Alan Melcher;Kelley Parato;Cliona M Rooney;John C Bell

  • The Case of Oncolytic Viruses Versus the Immune System: Waiting on the Judgment of Solomon

    Robin J. Prestwich;Fiona Errington;Rosa M. Diaz;Hardev S. Pandha

  • Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and Replication

    Robin J. Prestwich;Elizabeth J. Ilett;Fiona Errington;Rosa M. Diaz

  • Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity

    Fiona Errington;Lynette Steele;Robin Prestwich;Kevin J. Harrington

  • Oncolytic viruses: a novel form of immunotherapy

    Robin J.D. Prestwich;Kevin J. Harrington;Hardev S. Pandha;Richard G. Vile

  • Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity

    Robin J. Prestwich;Fiona Errington;Elizabeth J. Ilett;Ruth S.M. Morgan

  • Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8 + T cell trafficking

    David Taggart;David Taggart;Tereza Andreou;Karen J Scott;Jennifer Williams

  • Cell Carriers for Oncolytic Viruses: Fed Ex for Cancer Therapy

    Candice Willmon;Kevin Harrington;Timothy Kottke;Robin Prestwich

  • Measles virus causes immunogenic cell death in human melanoma

    Oliver G Donnelly;Fiona Errington-Mais;Lynette Steele;Elizabeth Hadac

  • Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients.

    Robert A. Adair;Victoria Roulstone;Karen J. Scott;Ruth Morgan

  • Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus

    Jian Qiao;Hongxun Wang;Timothy Kottke;Christine White

  • Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial.

    C L White;K R Twigger;L Vidal;L Vidal;J S De Bono

  • ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment

    Magnus T. Dillon;Katharina F. Bergerhoff;Malin Pedersen;Harriet Whittock

  • Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies

    Eleni Karapanagiotou;Victoria Roulstone;Katie Twigger;Mercel Ball

Frequent Co-Authors

Richard G. Vile
Richard G. Vile Mayo Clinic
Kevin J. Harrington
Kevin J. Harrington Royal Marsden NHS Foundation Trust
Peter Selby
Peter Selby University of Leeds
Timothy Kottke
Timothy Kottke Mayo Clinic
Matthew C. Coffey
Matthew C. Coffey Oncolytics Biotech (Canada)
Christopher M. Nutting
Christopher M. Nutting Royal Marsden NHS Foundation Trust
Michael J. Gough
Michael J. Gough Providence Portland Medical Center
Gerard J. Nuovo
Gerard J. Nuovo The Ohio State University
Stephen Todryk
Stephen Todryk Northumbria University
Atique U. Ahmed
Atique U. Ahmed Northwestern University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in advancing their career in healthcare alongside or after studying Immunology, exploring nursing pathways can be valuable. Many students consider programs like Licensed Practical Nurse (LPN), which serve as foundational steps into clinical practice. If convenience and admission ease are priorities, researching which LPN programs are easiest to get into can help identify accessible options.

For more specialized roles, becoming a Nurse Practitioner (NP) is a popular choice. There are many online options designed to simplify the transition with flexible curriculums. Identifying the easiest nurse practitioner program to enroll in may be beneficial for those seeking an efficient path to advanced practice.

If your focus is mental health within immunology-related fields, Psychiatric Mental Health Nurse Practitioner (PMHNP) programs are worth exploring. Discovering the top PMHNP programs ensures quality training and strong clinical placement opportunities. Balancing quality and cost, you might also want to consider the affordable PMHNP programs that make education more financially accessible without compromising standards.

Choosing the right degree path depends on your career goals, budget, and the level of patient care you wish to provide. These nursing pathways complement immunology knowledge, opening doors to impactful healthcare roles nationwide.

Best Scientists Citing Alan Melcher

Trending Scientists

Recently Published Articles